Abstract 2087P
Background
Cancer symptoms (CS) impose a significant burden on patients, affecting their quality of life and financial stability. The purpose of this study was to investigate the impact of common CS on the physical and financial well-being of patients who frequently rely on medications to manage their cancer-related symptoms.
Methods
A cross-sectional, descriptive study was conducted between January and October 2022. The study aimed to identify patient-administered drugs for managing cancer treatment toxicities and associated symptoms. It assessed six common symptoms: anorexia/cachexia, fatigue, nausea/vomiting, pain, constipation, and diarrhea. Demographic data were collected, along with cancer type and active treatment status. Symptom assessment used PERSONS questionnaire, while financial distress (FD) was analyzed with the COST questionnaire.
Results
A total of 211 patients completed the questionnaires, providing valuable insights into their symptom management. However, 183 patients, relied on prescription drugs to alleviate their symptoms. Cancer pain (CP) management was the primary concern for 45% of the patients, followed by constipation, which affected 28% of them. Significantly, the analysis revealed a strong association between CP and lower PERSONS scores, suggesting a negative impact on overall well-being. CP was also correlated with FD, unlike other symptom categories, which did not show statistically significant correlations. Healthcare costs were primarily attributed to pain management, including visits to healthcare professionals and prescription medications. Pain-related expenses contributed to financial strain, resulting in increased out-of-pocket costs and potential income loss due to reduced work productivity or inability to work.
Conclusions
This survey highlights the profound impact of CP on the quality of life and financial well-being of cancer patients. Collaborative efforts among healthcare professionals and policymakers are crucial in developing integrated approaches that ensure accessible and affordable pain management for cancer patients, thus alleviating their suffering and reducing the financial burden associated with pain.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Giusti.
Funding
Has not received any funding.
Disclosure
R. Giusti: Financial Interests, Personal, Expert Testimony, Advisory Board for Clinician's expertise on Drug Management: Roche; Financial Interests, Personal, Invited Speaker, Publication fee for open access manuscript: Molteni; Financial Interests, Personal, Advisory Board, Advisory Board: Novartis, Pfizer; Financial Interests, Personal, Invited Speaker to national and international congress: Angelini Pharma; Financial Interests, Personal, Expert Testimony, Expert testimony on Drug Management: Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06